Disease · MONDO_0020804
Comparisons in its trials39
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 39
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vismodegib - Locally Advanced vs Vismodegib - Metastatic: deaths from any cause | 103 of 1,119 | 19 of 96 | 1,215 | NCT01367665 | Trial comparisons |
| Vismodegib - Locally Advanced vs Vismodegib - Metastatic: serious adverse events | 272 of 1,119 | 31 of 96 | 1,215 | NCT01367665 | Trial comparisons |
| BF-200 ALA vs Methyl-aminolevulinate: deaths from any cause | 0 of 138 | 1 of 143 | 281 | NCT02144077 | Trial comparisons |
| BF-200 ALA vs Methyl-aminolevulinate: serious adverse events | 3 of 138 | 7 of 143 | 281 | NCT02144077 | Trial comparisons |
| LDE225 200 mg qd vs LDE225 800 mg qd: deaths from any cause | 1 of 79 | 7 of 150 | 229 | NCT01327053 | Trial comparisons |
| LDE225 200 mg qd vs LDE225 800 mg qd: serious adverse events | 16 of 79 | 58 of 150 | 229 | NCT01327053 | Trial comparisons |
| Vismodegib Intermittent Schedule vs Vismodegib Induction Followed by Intermittent Schedule: serious adverse events | 24 of 114 | 23 of 113 | 227 | NCT01815840 | Trial comparisons |
| BF-200 ALA vs Vehicle: deaths from any cause | 0 of 145 | 0 of 42 | 187 | NCT03573401 | Trial comparisons |
| BF-200 ALA vs Vehicle: serious adverse events | 3 of 145 | 2 of 42 | 187 | NCT03573401 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: deaths from any cause | 0 of 87 | 0 of 87 | 174 | NCT03703310 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: serious adverse events | 5 of 87 | 7 of 87 | 174 | NCT03703310 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: Percentage of Participants Developing >=2 Facial New BCCs | 45 of 83 | 55 of 86 | 169 | NCT03703310 | Trial comparisons |
| Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: Percentage of Participants Developing >=1 Facial New BCCs | 56 of 83 | 65 of 86 | 169 | NCT03703310 | Trial comparisons |
| Group 1: Metastatic BCC (mBCC) vs Group 2: Unresectable Locally Advanced BCC (laBCC): deaths from any cause | 22 of 54 | 21 of 84 | 138 | NCT03132636 | Trial comparisons |
| Group 1: Metastatic BCC (mBCC) vs Group 2: Unresectable Locally Advanced BCC (laBCC): serious adverse events | 18 of 54 | 33 of 84 | 138 | NCT03132636 | Trial comparisons |
| Metvix® PDT vs Cryotherapy: deaths from any cause | 4 of 60 | 3 of 58 | 118 | NCT00469417 | Trial comparisons |
| Metvix® PDT vs Cryotherapy: serious adverse events | 7 of 60 | 2 of 58 | 118 | NCT00469417 | Trial comparisons |
| Metvix® Cream 160 Milligram Per Gram vs Placebo: deaths from any cause | 1 of 33 | 0 of 33 | 66 | NCT00472043 | Trial comparisons |
| Metvix® Cream 160 Milligram Per Gram vs Placebo: serious adverse events | 1 of 33 | 2 of 33 | 66 | NCT00472043 | Trial comparisons |
| Photodynamic Therapy (PDT) With Metvix Cream 160 Milligrams/Gram (mg/g) vs Photodynamic Therapy (PDT) With Placebo Cream: Number of Participants With Clinically Evaluated Complete Response | 28 of 33 | 15 of 32 | 65 | NCT00472108 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020804/comparisons